Richard Brudnick

Richard H.
Brudnick currently works at InflaRx NV, as Independent Non-Executive Director from 2019, Scholar Rock Holding Corp., as Independent Director from 2023, Volition America, Inc., as Independent Director from 2021, Israel Biotech Fund, as Venture Advisor from 2018, and Prime Medicine, Inc., as Chief Business Officer from 2022.
Mr. Brudnick also formerly worked at James Brudnick Co., Inc., as President & Chief Executive Officer from 1984 to 1998, VolitionRX Ltd., as Independent Director from 2021 to 2023, Tamarix Pharma Ltd, as Director, Biogen, Inc., as Senior VP-Corporate Development & Strategy from 2014 to 2016, Codiak BioSciences, Inc., as Chief Business Officer & Head-Strategy from 2018 to 2022, and Bioverativ, Inc., as Executive Vice President-Business Development from 2016 to 2018.
Mr. Brudnick received his undergraduate degree in 1978 from Massachusetts Institute of Technology, Masters Business Admin degree in 1980 from MIT Sloan School of Management, and undergraduate degree and graduate degree from MIT Sloan School of Management.